Optimal strategies for monitoring response to antiretroviral therapy in HIV-infected adults, adolescents, children and pregnant women: A systematic review

AIDS

Volumn 28, Issue SUPPL. 2, 2014, Pages

  Tucker, Joseph D ^a,b,c   Bien, Cedric H ^a   Easterbrook, Philippa J ^d   Doherty, Meg C ^d   Penazzato, Martina ^d   Vitoria, Marco ^d   Peeling, Rosanna W ^c  

^a UNC Project China   (China)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

antiretroviral therapy; HIV; immunologic; monitoring; systematic review; virologic; WHO

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHILD; CLINICAL MONITORING; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGIC MONITORING; MONITORING; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIROLOGIC MONITORING; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

EID: 84901449278     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000230     Document Type: Review

References (59)

1. UNAIDS. Report on the global AIDS epidemic 2013. Geneva, Switzerland: UNAIDS; 2013.
2. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach [2010 revision]. Geneva: World Health Organization; 2013, http://whqlibdoc.who.int/ publications/2010/9789241599764-eng.pdf. [Accessed 26 January 2014]
3. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource limited settings. Lancet 2006; 368:505-510.
4. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. [2006 revision]. Geneva: World Health Organization; 2006, http://www.who.int/hiv/pub/ guidelines/artadultguidelines.pdf. [Accessed 26 January 2014]
5. World Health Organization. Antiretroviral therapy for HIV infection in infants and children towards universal access: recommendations for a public health approach. [2006 revision]. Geneva: World Health Organization; 2006, http://www. who.int/hiv/pub/guidelines/paediatric020907.pdf. [Accessed 17 May 2013]
6. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach [2010 revision]. Geneva: World Health Organization; 2010, http://whqlibdoc.who.int/ publications/2010/9789241599764-eng.pdf. [Accessed 26 January 2014]
7. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach [2010 revision]. Geneva: World Health Organization; 2010, http://whqlibdoc. who.int/publications/2010/9789241599801-eng.pdf. [Accessed 26 January 2014]
8. Walker AS, Gibb DM. Monitoring of highly active antiretroviral therapy in HIV infection. Curr Opin Infect Dis 2011; 24:27-33.
9. Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, Sankale JL, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis 2011; 53:1283-1290.
10. Rutherford GW, Anglemyer A, Easterbook PJ, Horvath T, Vitoria M, Penazzato M, Doherty MC. Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure. AIDS 2014; 28 (Supp 2):S161-S169.
11. Wilson D, Keiluhu AK, Kogrum S, Reid T, Seriratana N, Ford N, et al. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans Royal Soc Trop Med Hygiene 2009; 103:601-606.
12. UNITAID. HIV/AIDS diagnostics technology landscape. Geneva: UNITAID; 2012.
13. Easterbrook PJ, Irvine CJ, Vitoria M, Shaffer N, Muhe LM, Negussie EK, et al. Developing the 2013 WHO consolidated antiretroviral guidelines. AIDS 2014; 28 (Supp 2):S93-S100.
14. Ford N, Calmy A, Andrieux-Meyer I, Hargreaves S, Mills EJ, Shubber Z. Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. AIDS 2013; 27:1135-1143.
15. Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Thery F, Shaffer N, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS 2013; 27:1403-1412.
16. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
17. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ, et al. What is "quality of evidence" and why is it important to clinicians? BMJ 2008; 336:995-998.
18. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-926.
19. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 2010; 7:e1000251.
20. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370:1453-1457.
21. Sutton AJ. Methods for meta-analysis in medical research. Chichester, NY: John Wiley; 2000.
22. Barry C. Relationship of viral resistance development to CD4 monitoring alone or with viral load monitoring. ClinicalTrials. gov; 2013. http://clinicaltrials.gov/show/NCT00434070. [Assessed on 15 January 2014]
23. Abouyannis M, Menten J, Kiragga A, Lynen L, Robertson G, Castelnuovo B, et al. Development and validation of systems for rational use of viral load testing in adults receiving first-line ART in sub-Saharan Africa. AIDS 2011; 25:1627-1635.
24. Albrecht M, Lisa Mukherjee A, Tierney C, Morse GD, Dykes C, Klingman KL, et al. A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitorbased regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study. HIV Clin Trials 2011; 12:201-214.
25. Babiker A, Castronee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, et al. First-line antiretroviral therapy with a protease inhibitor versus nonnucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 2011; 11:273-283.
26. Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resourcelimited settings. AIDS 2003; 17:541-545.
27. Collazos J, Knobel H, Casado JL. CD4 count and viral load timecourses in patients treated with highly active antiretroviral therapy and association with the CDC staging system. HIV Med 2006; 7:504-513.
28. Davies M-A, Boulle A, Eley B, Moultrie H, Technau K, Rabie H, et al. Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy-The IeDEA Southern Africa Collaboration Précision. Trop Med Int Health 2011; 16:1367-1371.
29. Diaz T, Loth G, Whitworth J, Sutherland D. Surveillance methods to monitor the impact of HIV therapy programmes in resource-constrained countries. AIDS 2005; 19:S31-S37.
30. Duong T, Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Kantipong P, Buranabanjasatean S, et al. Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand. PLoS One 2012; 7:e43375.
31. FeregrinoGoyos M, GomezCaro HH, MirelesVieyra MP, AlvaradoDiez R, HigueraRamirez F, Hidalgo H. Viral load count as a better guide for antiretroviral therapy of HIV patients, the Mexican experiences. AIDS 1996; 10:69-169.
32. Kanapathipillai R, McGuire M, Mogha R, Szumilin E, Heinzelmann A, Pujades-Rodriguez M. Benefit of viral load testing for confirmation of immunological failure in HIV patients treated in rural Malawi. Trop Med Int Health 2011; 16:1495-1500.
33. Keiser O, MacPhail P, Boulle A, Wood R, Schechter M, Dabis F, et al. Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health 2009; 14:1220-1225.
34. Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, et al. Inferior clinical outcome of the CD4(R) cell count guided antiretroviral treatment interruption strategy in the SMART study: role of CD4(R) cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197:1145-1155.
35. Lynen L, An S, Koole O, Thai S, Ros S, De Munter P, et al. An algorithm to optimize viral load testing in HIV-positive patients with suspected first-line antiretroviral therapy failure in Cambodia. J Acquir Immune Defic Syndr 2009; 52:40-48.
36. Moore DM, Awor A, Downing R, Kaplan J, Montaner JS, Hancock J, et al. CD4R T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49:477-484.
37. Kekitiinwa RA, Sekadde M, Kitaaka SB, Kalyesubula I, Pitter C, Thomas D, et al. Viral load monitoring is critical to assess early paediatric response to highly active antiretroviral therapy in a resource limited setting: the Ugandan experience. International Conference on AIDS (16th: 2006: Toronto, Canada); 13 August 2006; Toronto, ON.
38. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23-31.
39. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Traisaithit P, Barbier S, Techapornroong M, et al. PHPT-3: a randomized clinical trial comparing CD4 vs viral load ART monitoring/switching strategies in Thailand. 18th Conference on Retroviruses and Opportunistic Infections; 27 February 2011; Boston, MA.
40. Keiser O, Chi BH, Gsponer T, Boulle A, Orrell C, Phiri S, et al. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa. AIDS 2011; 25:1761-1769.
41. Laurent C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Mbougua JB, Boyer S, et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus CM alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised noninferiority trial. Lancet Infect Dis 2011; 11:825-833.
42. Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, Kaharuza F, et al. Utility of routine viral load, CD4 cell count, and CM among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ 2011; 343:d6792.
43. ARROW Trial Team. Kekitiinawa A, Cook A, Nathoo K, Mugyenyi P, Nahirya-Ntege P, Bakeera-Kitaka S, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet 2013; 381:1391-1403.
44. Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised noninferiority trial. Lancet 2010; 375:123-131.
45. Chang LW, Harris J, Humphreys E. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings. Cochrane Database Syst Rev (2010):CD008494.
46. Lifson AR, Krantz EM, Grambsch PL, Macalino GE, Crum-Cianflone NF, Ganesan A, et al. Clinical, demographic and laboratory parameters at HAART initiation associated with decreased post-HAART survival in a U.S. military prospective HIV cohort. AIDS Res Ther 2012; 9:4.
47. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008; 22:2097-2106.
48. Gsponer T, Petersen M, Egger M, Phiri S, Maathuis MH, Boulle A, et al. The causal effect of switching to secondline ART in programmes without access to routine viral load monitoring. AIDS 2012; 26:57-65.
49. Belec L, Bonn JP. Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less. Future Microbiol 2011; 6:1251-1260.
50. Suthar AB, Ford N, Bachanas PJ, Wong VJ, Rajan JS, Saltzman AK, et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of communitybased approaches. PLoS Med 2013; 10:e1001496.
51. Koenig SP, Leandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS 2004; 18 (Suppl 3):S21-S25.
52. Peeling RW, Ronald A. Diagnostic challenges of sexually transmitted infections in resource-limited settings. Future Microbiol 2009; 4:1271-1282.
53. Louis FJ, Anselme R, Ndongmo C, Buteau J, Boncy J, Dahourou G, et al. Evaluation of an external quality assessment program for HIV testing in Haiti, 2006-2011. Am J Clin Pathol 2013; 140:867-871.
54. Damond F, Benard A, Balotta C, Boni J, Cotten M, Duque V, et al. An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study. J Clin Microbiol 2011; 49:3491-3497.
55. Damond F, Benard A, Ruelle J, Alabi A, Kupfer B, Gomes P, et al. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J Clin Microbiol 2008; 46:2088-2091.
56. Kawonga M, Blaauw D, Fonn S. Aligning vertical interventions to health systems: a case study of the HIV monitoring and evaluation system in South Africa. Health Res Policy Syst 2012; 10:2.
57. Kawonga M, Fonn S, Blaauw D. Administrative integration of vertical HIV monitoring and evaluation into health systems: a case study from South Africa. Glob Health Action 2013; 6: 19252.
58. Hamers RL, Sawyer AW, Tuohy M, Stevens WS, Rinke de Wit TF, Hill AM, et al. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS 2012; 26:1663-1672.
59. Medina Lara A, Kigozi J, Amurwon J, Muchabaiwa L, Nyanzi Wakaholi B, Mujica Mota RE, et al. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe. PLoS One 2012; 7:e33672.